AbbVie (ABBV) Stock: Price, Trend, Options & Financials
AbbVie's price regime, relative strength, unusual-options history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
ABBV closed at $264.96 on Aug 21, 2026. The price is +6.8% from its 50-day average and +16.9% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +23.5%, beating SPY by 20.4%. It remains 0.9% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is +6.8% from its 50-day average and +16.9% from its 200-day average. Over three months, ABBV returned +23.5% versus +3.1% for SPY.
- vs 50-day
- +6.8%
- vs 200-day
- +16.9%
- From 52W high
- -0.9%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
ABBV appeared in a UOA top-30 list on 4 of 62 archived scanner sessions: 4 call-side, 0 put-side and 0 on both lists. The latest session did not place it in either top 30. Its larger composite score was -0.19, below the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-08-07 | #15 | — |
| 2026-06-15 | #13 | — |
| 2026-06-09 | #17 | — |
| 2026-05-26 | #26 | — |
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.163 calls, 0.050 puts.
Curated-manager ownership
None of the 20 managers in the project's curated 13F set reported a long AbbVie position in their latest filing. That is an explicit absence within this focused panel, not evidence that the company has no institutional holders.
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open ABBV Financials →How ABBV trades — the working manual
AbbVie is a biopharmaceutical company spanning immunology, oncology, neuroscience and aesthetics. For the stock, the central question is whether newer medicines and acquired franchises can replace mature-product erosion while preserving margins and funding the research, business development and debt reduction needed for the next cycle.
What can move the tape
- 01Prescription growth, market share and indication expansion for the immunology portfolio.
- 02Revenue durability in neuroscience, oncology and aesthetics franchises.
- 03Clinical readouts, regulatory decisions and the commercial ramp of pipeline medicines.
- 04Operating margin, cash generation, acquisition integration and debt reduction.
What can fool the read
- 01Loss of exclusivity and biosimilar competition can accelerate erosion in major products.
- 02Pipeline setbacks can leave a larger gap between mature franchises and future revenue.
- 03Drug-pricing policy and payer access can affect both volume and realized price.
- 04Acquisition assumptions can disappoint while leverage limits capital-allocation flexibility.
No ABBV flags in the committed 2026-04-01–2026-08-21 archive. That means no session cleared this project's anomaly threshold; it does not mean trading volume was literally constant.
Not published yet. The local archive has 1 reported ABBV events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-16 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
ABBV stock questions
Is ABBV stock in an uptrend?+
ABBV is classified in the “established uptrend” regime as of 2026-08-21: the close is +6.8% from its 50-day average and +16.9% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in ABBV mean?+
AbbVie's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the ABBV 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are ABBV's income statement and cash flow?+
The dedicated ABBV Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no ABBV earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.